Why Are We Surrendering to COVID?
PharmExec
JUNE 14, 2022
Industry must continue research and development to combat the pandemic.
PharmExec
JUNE 14, 2022
Industry must continue research and development to combat the pandemic.
Outsourcing Pharma
JUNE 14, 2022
During BIO International, US leaders shared lessons learned from COVID-19, and how government and industry are collaborating to avoid future supply chain crises.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 14, 2022
Eli Lilly and Incyte’s Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 people in the US. The JAK1/2 inhibitor has been cleared for adults who are severely affected with the condition at a dose of 2mg once-daily, which can be stepped up to 4mg/day if needed, and according to the FDA will “help fulfil a significant unmet need for patients.” It is estimated tha
Outsourcing Pharma
JUNE 14, 2022
The company has completed its early-phase development and manufacturing facility in Bend, giving it 11 processing suites focused on first steps into the clinic.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
JUNE 14, 2022
An alliance between Spanish drugmaker Almirall and digital health company Happify has yielded its first fruit, with the launch of their Claro app designed to reduce anxiety and improve wellbeing in people with psoriasis. The web-based app is rolling out first in the UK, Spain and Italy and is aimed at the 20% to 30% of patients with moderate to severe psoriasis who also suffer from mental health issues, according to the partners.
PharmExec
JUNE 14, 2022
A roadmap for cohering patient perspectives.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Times
JUNE 14, 2022
The three-year project will focus on molecular representations and computational tools
Viseven
JUNE 14, 2022
Once there’s an inquiry about how to improve pharmaceutical sales representatives’ performance, there’s a need to ask a simple question: “What does it mean to be a pharmaceutical representative? What is exactly a pharma rep’s responsibility zone?” Looking for the answer, you may find that the key role of a pharma representative is to deliver the pharma company’s ideas and messages to the health care reps in a most efficient, understandable, and intelligi
PharmExec
JUNE 14, 2022
Wednesday June 15, 2022 from 11am EDT | 8am PDT| 4pm BST | 5pm CEST IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients.
pharmaphorum
JUNE 14, 2022
Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler, more patient-friendly dosing regimen. ATTR amyloidosis is an aggressive, rapidly progressing, debilitating and fatal disease, and the launch of Alnylam’s earlier Onpattro (patisiran) in 2018 for polyneuropathy associated with the disorder was a massive step forward for patients.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Outsourcing Pharma
JUNE 14, 2022
The newly launched CDMO plans to set up two new manufacturing lines, after expanding into a 5,000-square-meter manufacturing facility.
Pharma Times
JUNE 14, 2022
Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours
Pharma Manufacturing
JUNE 14, 2022
Comprehensive strategies to save time and reduce cost in end-to-end clinical development
Pharmaceutical Commerce
JUNE 14, 2022
Configurable applications address patient and healthcare-provider interfaces, and an analytics dashboard.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JUNE 14, 2022
China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the global pipeline. Despite more treatment options being a positive, Ben Hargreaves finds that this has raised issues over single-region clinical trials, leading to the FDA rejecting certain treatments and clarifying what is required for approval.
Pharmaceutical Commerce
JUNE 14, 2022
Expanded partnership revolves around hemophilia A therapeutics.
Let's personalize your content